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Introduction
Regulatory T cells (Tregs) are implicated in controling graft-
versus-host disease (GvHD) post allogeneic hematopoietic
stem cell transplantation (HSCT)1 prompting the quest for
novel therapies based on their adoptive transfer. 
Initial studies to prevent or treat GvHD2,3 were based on the
infusion of freshly isolated naturally occurring Tregs (nTregs)
circulating in peripheral blood.4 Even though these studies
established the overall safety of Treg-based therapies, they
also clearly indicated that the low numbers of Tregs collected
from the peripheral blood are inadequate for controlling
GvHD.5 Given these limitations, protocols aimed at effective-
ly selecting and expanding ex vivo fully functional nTregs in
compliance with Good Manufacturing Practice (GMP) are
badly needed.
Here we describe a simplified and cost-effective methodol-
ogy that consistently and reproducibly expands nTregs that
retain potent inhibitory function both in vitro and in vivo.
Design and Methods
Isolation of nTregs and culture conditions
Buffy coats were obtained from healthy volunteer donors (Gulf
Coast Regional Blood Center, Houston, TX, USA) (IRB H-7634).
Putative nTregs (CD4+CD25Bright) were enriched from peripheral blood
mononuclear cells (PBMC) using positive selection, after labeling cells
with a minimal amount of CD25-specific microbeads (2 mL/107 cells;
Miltenyi Biotec Inc., Auburn, CA, USA).2,6 Immediately after selection
(Day 1), CD25Bright cells (106 cells/mL) were resuspended in complete
medium, consisting of RPMI1640 (Hyclone, Logan, UT, USA), 10%
AB-human serum (Valley Biomedical, Winchester, VA, USA), 2 mM L-
glutamine (BioWhittaker Inc., Walkersville, MD, USA), penicillin-
streptomycin (BioWhittaker), and b-mercaptoethanol (50 mM)
(Invitrogen, Carlsbad, CA, USA) and then activated with anti-CD3
(OKT3, Orthoclone, Cilag Ag Int., Zug, Switzerland) (1 mg/mL) and
anti-CD28 monoclonal antibodies (mAb) (1 mg/mL)6 (BD Biosciences
PharMingen, San Diego, CA, USA) in the presence of temsirolimus
(LC Laboratories, Woburn, MA, USA) at a final concentration of 100
nM.7 On Day 7 (S1), cells were harvested, washed, counted and seed-
ed in a G-Rex108 (Wilson Wolf Manufacturing, Saint Paul, MN, USA)
(http://www.wilsonwolf.com/) and supplemented with soluble OKT3 (1
mg/mL), CD28 mAb (1 mg/mL), rIL-2 (50 IU/mL)6 (Proleukin; Chiron,
Emeryville, CA, USA), temsirolimus (100 nM) and irradiated (40 Gy)
allogeneic feeders obtained from at least two pooled CMV-seronega-
tive donors meeting testing requirements for whole blood donation
(1:5 Treg:feeders ratio). On Day 14 (S2), cells were seeded in the G-
Rex1008 and supplemented with the same reagents used in S1. On
Day 21 (S3), cells were harvested, counted and used for functional
experiments. CD25 depleted cells (CD25Dep) expanded in parallel
without temsirolimus were used as control cells. To further validate
our approach for clinical use, putative nTregs were isolated using the
CliniMACS device. Briefly, PBMC were labeled with clinical grade
CD25-specific microbeads (18 mL buffer and 2 mL of beads for 1 x 107
cells). After incubation and washes, cell selection was then started
according to E-cell System software version 3.2. At the end of the
selection, cells were expanded as described for small-scale experi-
ments. On Days 14 (S2) and 21 (S3), aliquots of expanded Tregs were
cryopreserved in dimethyl sulfoxide (DMSO) according to standard
procedure and stored in liquid nitrogen.
Results and Discussion
Naturally occurring Tregs undergo robust ex vivo expansion
in the G-Rex device 
The methodology to isolate and expand nTregs is graphi-
cally summarized in the Online Supplementary Figure S1. To
reduce the complexity of the process of selection from the
peripheral blood, we isolated putative nTregs exclusively
based on their bright expression of the CD25 molecule
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ABSTRACT
(CD25Bright cells) without additional selection steps. Starting
from 4.5x108±1x108 PBMC (obtained from 50 mL of buffy
coat products), we recovered 3x106±1x106 cells. Upon
selection, these cells consistently co-expressed CD4 and
CD25 molecules (95%±5%), with limited contamination
by CD8+ cells. On Day 7 (S1) and Day 14 (S2),
2.9x106±0.5x105 and 7.7x107±1.7x107 cells were obtained,
respectively. After the third stimulation (Day 21, S3), we
recovered 1.8x109±7.6x107 cells, corresponding to an over
600-fold expansion (Figure 1A). This degree of expansion
was significantly higher than that obtained in parallel
experiments (5-6 fold) in which isolated nTregs were
grown using the same protocol but plated in conventional
24-well tissue culture plates (cells at Day 21 were
5.3x106±1.6x106 starting from 1x106) (Figure 1B). The per-
centage of CD4+CD25+ cells remained stable over three
weeks of culture and was 92±5% by Day 21, with
69±19% of the cells expressing FoxP3 (Figure 1C and D).
Expanded nTregs retained their expression of the lymph
node homing molecules CD62L and CCR7 (69±4% and
39±3%, respectively), and lacked expression of the IL-7Ra
(CD127) (2±1.2%), a known feature of Tregs.9 Of note, the
percentage of FoxP3+ cells significantly increased from
Day 1 to Day 21 of culture. FoxP3 promoter remained con-
sistently unmethylated indicating the commitment of the
expanded cells to the Treg state, despite some of them
lacking FoxP3 protein expression by Day 21 of culture
(Figure 1E).10 In contrast, the FoxP3 promoter of cultured
CD25Dep control cells remained consistently methylated
(Figure 1E). The phenotypic analysis of CD25Dep cells after
three stimulations (S3) showed that CD4, CD25, FoxP3,
CCR5 and CCR7 were expressed by 55±21%, 7±6.5%,
12±11%, 9±7%, and 11±5% of the cells, respectively.
Ex vivo expanded nTregs maintain robust suppressive
activity without undergoing senescence
Using a CFSE-based suppression assay, we found equal
suppression of T-cell divisions by either freshly isolated
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Figure 1. Robust ex vivo expansion of nTregs in the G-Rex device. (A) illustrates the number of nTregs obtained after 1, 2 or 3 (S1, S2 and
S3) weeks of culture in the G-Rex device. Data illustrate average and standard deviations (SD) for 7 independent experiments. (B) Compares
the fold expansions of nTregs cultured in 24-well plates or in the G-Rex device. Data show mean ± SD of 7 independent experiments. (C)
Shows the flow cytometry plots of expanded nTregs on Day 21 (S3). The panels illustrate CD4, CD25, CCR7, CD127 and FoxP3 expression
for one representative donor. (D) Illustrates the expression of CD25, CD4 and FoxP3 in expanded nTregs after each round of stimulation (S1,
S2 and S3). Data summarize the results of 7 independent experiments. (E) Shows the methylation-specific semi-quantitative PCR of the
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nTregs or expanded nTregs (S3) (80±10% and 80±13% sup-
pression, respectively) (P<0.0001). No suppression was
observed in the presence of expanded control CD25Dep cells
(12±9% suppression) (Figure 2A and B). Importantly, the
robust expansion of nTregs achieved in the G-Rex device
was obtained without significantly compromising their
telomere length. In freshly isolated nTregs (Day 1) and
expanded nTregs at S1, S2 and S3, relative telomerase
length (RTL) was 3.4±0.96%, 3±0.98%, 3±0.99%,
2.8±1.8%, respectively (Figure 2C), suggesting that, in addi-
tion to cell divisions, a significant preservation of cell viabil-
ity contributes to the large number of cells expanded in the
G-Rex device. Since by Day 21, expanded nTregs contained
contaminating CD8+ cells (10±3.7%), we specifically
assessed the functionality of these cells, as the infusion of
functional CD8+ cells in the allogeneic HSCT setting may
exacerbate GvHD and thus compromise the protective
effects of Tregs. As illustrated in Figure 2D and E, T-cell divi-
sions were suppressed equally well when either freshly iso-
lated nTregs, expanded nTregs or selected CD8+ cells were
added to the culture (80±8%, 76±8%, and 66±14% sup-
pression, respectively) (P<0.001), suggesting that contami-
nating CD8+ cells likely acquired inhibitory properties dur-
ing the ex vivo culture conditions. This inhibitory function of
expanded CD8+ cells was corroborated by the detection of
the unmethylated form of the FoxP3 promoter in these cells
(Figure 2F). Even if we cannot exclude that some of the con-
taminating CD8+ cells have effector function, experiments
in which the suppression assays were performed using dif-
ferent ratios of CD8+ cells and T-effector cells showed that
Grex-mediated expansion of Tregs
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Figure 2. Ex vivo expanded nTregs retain robust suppressive function without undergoing cell senescence. (A) The inhibitory activity of freshly
isolated nTregs, expanded nTregs (S3), and expanded CD25Dep cells was assessed using a CFSE-based suppression assay. Panels illustrate
the inhibitory activity of nTregs for a representative experiment. (B) The graph summarizes average and SD of the inhibitory function of
nTregs for 7 independent experiments. (C) The graph illustrates the relative telomerase length (RTL) in freshly isolated nTregs (Day 1) and
expanded nTregs at S1, S2 and S3. Data show mean ± SD for 7 independent experiments. (D) Contaminating CD8+ cells at Day 21 of culture
were isolated and analyzed for their suppressive activity and compared to nTregs. Panels illustrate the inhibitory activity for one representa-
tive experiment. (E) The graph summarizes average and SD of the inhibitory function of contaminating CD8+ cells and nTregs for 7 independ-
ent experiments. (F) Methylation-specific semi-quantitative PCR of FoxP3 promoter in cells obtained at the end of third round of stimulation
(S3), nTregs obtained at the end of the third round of stimulation depleted of CD8 (S3-Expanded CD8), the expanded and purified CD8+ cells
in S3 (Expanded CD8 + Rapa), CD25Dep population (CD8–Rapamycin), and PBMC. (G) Illustrates the expression of FoxP3 (after three stimu-
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their overall inhibitory function was significantly retained
at 1:10 dilution (Online Supplementary Figure S2). The pheno-
typic analysis of these CD8+ cells showed that 25±13% of
them expressed FoxP3 and 11±1.6% and 22±2.3%
expressed CCR5 and CCR7, respectively (Figure 2G).
Expanded nTregs control GvHD in a xenogeneic 
mouse model
To investigate whether expanded nTregs retained their
inhibitory function in vivo, we used a xenograft model of
lethal GvHD.11 As illustrated in Figure 3A, the weight loss
of control mice receiving PBMC and CD25Dep cells was sig-
nificantly greater as compared to mice that received
PBMC and expanded nTregs (7.2±1.9 g vs.1.9±1 g, respec-
tively) (P=0.0045). In addition, by Day 60, mice receiving
expanded nTregs had delayed occurrence or no signs of
GvHD (Figure 3B), and showed normal sized spleen as
compared to controls (Figure 3C). Finally, mice co-infused
with expanded nTregs revealed no histopathological
lesions compatible with GvHD in their skin, nose, or ear
(Figure 3D), and showed significantly improved overall
survival as compared to control mice (P<0.0003) (Figure
3E). As illustrated in the Online Supplementary Figure S3A,
Tregs co-infused with PBMC did not abrogate the engraft-
ment of PBMC, suggesting that in this model Tregs inhibit
the expansion of T cells that cause the occurrence of
GvHD. Finally, as previously demonstrated by others,12
nTregs expanded in the presence of rapamycin did not
produce IL-17 (Online Supplementary Figure S3B).
nTregs selected and expanded using the CliniMACS
and G-Rex devices, respectively, maintain potent 
in vitro and in vivo suppressive function
To make our methodology GMP compliant, we adapted
the selection using the CliniMACS system. CD25Bright cells
(2.3x106 ± 0.7x106) were positively selected from PBMC
(4.6x108 ± 0.7x108) of 3 buffy coats, using clinical grade
anti-CD25 microbeads and expanded as described in the
R. Chakraborty et al.
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Figure 3. Expanded nTregs control GvHD in a xenogeneic mouse model. Irradiated NSG mice were infused with PBMC either alone or in com-
bination with expanded nTregs (S3) or expanded control CD25Dep cells at 1:1 ratio. (A) The graph illustrates the measurements of the weight
of the NSG mice. Data show mean ± SD of 12 animals for each group (*P=0.0001). (B) Images show that control mice developed signs of
GvHD, such as hair loss and orbital tightening. (C) Spleen enlargements were observed in mice infused with control CD25Dep cells. (D)
Representative H&E and immunohistochemistry staining for CD8+ cells in tissue sections obtained from skin, nose, ear, and spleen of treated
mice. Control mice showed evidence of chronic dermatitis, with moderate diffuse epithelial hyperplasia, hyperkeratosis and marked multi-
focal coalescing subcutaneous and dermal mononuclear inflammatory cell infiltrates. Arrows indicate infiltrating CD8+ cells. (E) Kaplan-
Meier survival curve comparing NSG mice receiving human PBMC alone or in combination with expanded nTregs or expanded control
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small scale experiments, resulting in 1.3x109±3x107 cells by
Day 21 of culture (S3) (Online Supplementary Figure S4A)
(547-fold expansion). These cells consistently co-expressed
CD4, CD25 (97±2%) and FoxP3 (82±4%) (Online
Supplementary Figure S4B and C), while the contaminating
CD8+ cells were less than 1.2±1%. The expanded Tregs
suppressed T-cell divisions in vitro (80±10% and 78±5%
suppression for expanded and freshly isolated Tregs,
respectively) (Online Supplementary Figure S4D), and main-
tained robust in vivo suppressive activity improving the
overall survival of mice (P=0.0046) (Online Supplementary
Figure S4E). Finally, because the infusion of freshly cultured
Tregs is frequently impractical for clinical applications and
a cryopreservation step is usually required for quality con-
trol tests, we evaluated whether expanded nTregs retained
their functionality following cryopreservation and storage
in liquid nitrogen. Expanded Tregs cryopreserved after Day
14 (FS2) or Day 21 (FS3) retained their suppressive activity
both in vitro (Online Supplementary Figure S5A) and in vivo
(Online Supplementary Figure S5B). 
Our proposed strategy has significant advantages com-
pared to other protocols.13,14 First, we have minimized the
cell purification process to a single immune magnetic
selection step based on their CD25 expression, which is
sufficient to minimize the contamination by CD8+CD25+
cells in the final Treg products, provided that rapalogs are
added to the cultures during the expansion phase.
Importantly, we have observed that, in the presence of
rapalogs, ‘contaminating’ CD8+CD25+ cells persisting at
the end of the 21 days of culture show inhibitory proper-
ties and methylation of FoxP3 promoter. This is in accor-
dance with previous observations showing that, in specific
culture conditions, CD8+ cells may develop suppressive
activity.10,15 Second, and most importantly, we have opti-
mized a robust and cost-effective expansion protocol of
Tregs. Stimulation of Tregs is obtained with anti-
CD3/CD28 mAbs, now available as clinical grade reagents
(Miltenyi Biotec Inc.), and feeder cells that meet GMP
requirements.16,17 In addition, cells are easily accommodat-
ed, with minimal manipulation, in small gas permeable
static culture flasks (G-Rex) that promote efficient gas
exchange and availability of nutrients to the cells, while
diluting waste products.
Remarkably, expanded Tregs had no significant shorten-
ing of their telomere lengths, indicating their potential
capacity to undergo further divisions in vivo after adoptive
transfer, and retained inhibitory function after freezing
and thawing. These are important manufacturing aspects
to be considered in clinical protocols of adoptive T-cell
therapy as quality control tests of the produced cells are
usually required. Hence, the cost-effective and simplified
production of nTregs we propose will likely facilitate the
implementation of clinical trials based on the infusion of
these cells to control GvHD after allogeneic HSCT and
graft rejection in solid organ transplant recipients, and to
treat autoimmune diseases.
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